drug

IL-23

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of Maryland, Baltimore County
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
NCT07615075Phase 4Not Yet Recruiting

KOLs & investigators

1
Deanna L. Kelly, Pharm.D., BCPPKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of Maryland, Baltimore County
company
trial
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
PHASE4
trial
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Healthy
indication
Schizophrenia
indication
KOL
Deanna L. Kelly, Pharm.D., BCPP
KOL score 5
person